A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
about
Pituitary somatostatin receptor signalingAcromegaly pathogenesis and treatmentPlace of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysisMeta-analysis on the effects of octreotide on tumor mass in acromegalyTemozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expressionMetabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Expert consensus document: A consensus on the medical treatment of acromegaly.Clinical review: Pituitary carcinoma: difficult diagnosis and treatmentMedical therapy of acromegalyLong-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.Treatment strategies for acromegaly.Recent developments in the therapy of acromegaly.Resistance to somatostatin analogs in acromegaly: an evolving concept?Peptide receptor targeting in cancer: the somatostatin paradigm.Nanomedicines in the treatment of acromegaly: focus on pegvisomant.Pegvisomant in acromegaly: why, when, how.Somatostatin agonists for treatment of acromegaly.Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.The role of primary pharmacological therapy in acromegaly.Multiple facets in the control of acromegaly.Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors.Octreotide long-acting repeatable for acromegaly.Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission.The place of medical treatment of acromegaly: current status and perspectives.Octreotide for acromegaly treatment: a reappraisal.Management of aggressive pituitary adenomas and pituitary carcinomas.Specific inhibition of mTOR pathway induces anti-proliferative effect and decreases the hormone secretion in cultured pituitary adenoma cells.Somatostatin receptor ligands in the treatment of acromegaly.Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.Treatment of Acromegaly: Are We Satisfied With the Current Outcome?Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy.Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study.First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
P2860
Q24631604-131DCE47-63D1-4C15-ABF9-46C37A9DCB43Q24647360-C074DA59-2751-4B55-872D-B8D8F9D4A55AQ27693237-E9EC92A0-5805-4057-8F4A-10B9A1A69F9DQ28730120-21C6D162-43F5-4CC6-9258-4ACC1458754EQ30353110-17789B38-404B-4A66-B3D4-BD257BE61993Q31139308-3A1BEA3C-E460-4A2E-A6D2-484AC5E18A41Q33564399-BF03174C-9C02-471F-8269-FDEFC4BF76C4Q33794409-C4AEF60C-594E-4CA2-B052-1A2875BD873FQ34031906-EF43A1A0-21FD-467E-9013-2E5EC0C9A876Q34406566-0194E046-E671-4483-92DB-A506386B92ABQ35750569-A26389B0-71A9-419B-B4D2-CA2A50BFC059Q35895856-37064109-12C0-426C-ABAB-191429526F15Q35987482-0F9E2BF5-A012-430A-917C-C2CB414EF78AQ35987499-B99C4A96-DAAB-4EB9-A8AA-C62FC165500CQ36302865-B7FEE352-7FD0-4BB7-BE29-6A8FA5B98BD5Q36407309-ACF66F3E-D9C4-4FF0-9110-72E23B937BC2Q36428225-59B7CE15-470B-415E-8A12-2579D64D5B1DQ36638046-1F5DA5B7-4F43-42E3-9283-9C087B22F770Q36920317-6CFFC65B-D716-47F7-84EF-A95CB28363B3Q36965612-294CCC31-6124-465F-BBED-F4FD6B3CB9D1Q37055643-50B4F84D-F3C5-4B6C-B142-C82DC172AA4AQ37244671-16F3C804-F356-46BB-8F64-EB363C3D30E5Q37321948-49D61222-D7B1-4900-9331-FCBF5D7597C0Q37519612-1554DC31-719C-48B3-828A-2174910C5F1AQ37531005-35F33E4B-8C0D-4CC4-A6C2-515CB3A2348BQ37531066-DD517626-32B1-4CEE-A395-7DEF6E52E1ABQ37941521-E66CF817-5507-4D8A-A24C-CA94C9B390DAQ37990556-C4138072-B959-405D-9DFA-1F0D46B197DCQ38062441-5E4860B9-9874-4387-AEAF-DF4639621E3EQ38100275-FB1D75B7-3727-4D13-91C5-1EDCE11CE22EQ38152458-AFA604D2-572D-426B-874C-C2A9845711A3Q38192486-0C049659-3E64-4DFE-BD59-4A5ED3C0B990Q38841865-1C547AF7-C4DC-4CEE-8575-F097E84B85D7Q39125449-05BE1F88-0FD1-4A9C-B66A-11D3001D8F08Q39957511-918F7DD3-7750-4581-B1E9-9A9B22999666Q41625092-682B5882-96CF-451D-969C-DE4B003A108FQ43078115-0D51BB5B-0683-4712-84BB-8B8A58FF969CQ43222345-1BE56DAA-BB68-47DF-AC7B-37B029476F99Q46147583-B70B02CA-8AE3-419D-9D20-8CD062EF9B5BQ46951312-3D29F1F5-8ED8-46F5-BED5-2B86694F5E5F
P2860
A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
A critical analysis of pituita ...... medical therapy in acromegaly.
@ast
A critical analysis of pituita ...... medical therapy in acromegaly.
@en
type
label
A critical analysis of pituita ...... medical therapy in acromegaly.
@ast
A critical analysis of pituita ...... medical therapy in acromegaly.
@en
prefLabel
A critical analysis of pituita ...... medical therapy in acromegaly.
@ast
A critical analysis of pituita ...... medical therapy in acromegaly.
@en
P2093
P356
P1476
A critical analysis of pituita ...... medical therapy in acromegaly.
@en
P2093
Ariel Barkan
David Cook
David Kleinberg
David Rhew
Mary Lee Vance
Philippe Chanson
Richard Sternberg
Shlomo Melmed
Vivien Bonert
P304
P356
10.1210/JC.2004-2466
P407
P577
2005-04-12T00:00:00Z